190 related articles for article (PubMed ID: 1790992)
1. [Comparison of the estrogen and progesterone receptor content of primary breast cancers without skeletal or visceral metastasis with tumor marker MCA, CEA and CA 15-3 serum concentration at the time of surgery].
Seifert M; Wierrani F; Kubista E; Spona J
Gynakol Rundsch; 1991; 31 Suppl 2():397-8. PubMed ID: 1790992
[No Abstract] [Full Text] [Related]
2. [Tumor markers in the diagnosis and prognosis of breast cancer].
Seliuzhitskiĭ IV; Skvortsov SV; Lytsar BN; Khomenko LP
Klin Med (Mosk); 1993; 71(2):25-7. PubMed ID: 8046917
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer.
Molina R; Filella X; Alicarte J; Zanon G; Pahisa J; Munoz M; Farrus B; Ballesta AM
Anticancer Res; 2003; 23(2A):1035-41. PubMed ID: 12820344
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic factors in breast cancer].
Jonat W; Eidtmann H; Friedrichs K
Gynakologe; 1994 Feb; 27(1):37-44. PubMed ID: 8168736
[No Abstract] [Full Text] [Related]
5. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
[TBL] [Abstract][Full Text] [Related]
6. [Carcinoembryonic antigen (CEA) and mucinous-like tumor associated antigen (MAC). Statistic correlation in advanced breast carcinoma].
Sbalzarini G; D'Agostino F; Mercantini F; Girami M; Labadini A; Pandolfi C
Minerva Med; 1991 Dec; 82(12):811-3. PubMed ID: 1780086
[TBL] [Abstract][Full Text] [Related]
7. [Tumor markers in metastatic breast carcinoma: correlations with clinical response].
Winer Y; Martini MC; Pastorino G; Moraglio L; Vallauri M; Brondi P; Brema F
J Nucl Med Allied Sci; 1990; 34(4 Suppl):127-30. PubMed ID: 2092107
[No Abstract] [Full Text] [Related]
8. Carcinoembryonic antigen in tissue and serum from breast cancer patients relationship with steroid receptors and clinical applications in the prognosis and early diagnosis of relapse.
Molina R; Farrus B; Filella X; Jo J; Zanón G; Pahisa J; Latre M; Muñoz M; Ballesta AM
Anticancer Res; 1999; 19(4A):2557-62. PubMed ID: 10470194
[TBL] [Abstract][Full Text] [Related]
9. The early detection of disseminated (metastasized) breast cancer by serial tumour marker measurements.
Jäger W
Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():133-9. PubMed ID: 8298443
[No Abstract] [Full Text] [Related]
10. Serum CEA, CA 15-3, and MCA in breast cancer patients: a clinical evaluation.
Repetto L; Onetto M; Gardin G; Costanzi B; Giudici S; Vitiello E; Merlini L; Naso C; Zannini C; Paganuzzi M
Cancer Detect Prev; 1993; 17(3):411-5. PubMed ID: 8402728
[TBL] [Abstract][Full Text] [Related]
11. Serum tumor markers in skeletal metastasis.
Tsukushi S; Katagiri H; Kataoka T; Nishida Y; Ishiguro N
Jpn J Clin Oncol; 2006 Jul; 36(7):439-44. PubMed ID: 16815865
[TBL] [Abstract][Full Text] [Related]
12. [Is follow-up of breast cancer with CEA and CA 15-3 justified?].
Fritsche E; Benz J
Helv Chir Acta; 1992 May; 59(1):225-9. PubMed ID: 1526832
[TBL] [Abstract][Full Text] [Related]
13. A decision support system for predicting a recurrence of breast cancer; a prospective study of serum tumour markers TAG 12, CA 15-3 and MCA.
Eskelinen M; Hippeläinen M; Carlsson L; Jonsson P; Alhava E
Anticancer Res; 1992; 12(5):1439-42. PubMed ID: 1444204
[TBL] [Abstract][Full Text] [Related]
14. [Tumor markers in human breast cancer].
Takami H; Shikata J
Gan To Kagaku Ryoho; 1987 Nov; 14(11):2998-3003. PubMed ID: 3479050
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of the receptor content and growth fraction of breast cancers and their axillary lymph node metastases].
Fleige B; Pickartz H; Stein H
Pathologe; 1989 Jan; 10(1):12-5. PubMed ID: 2646629
[No Abstract] [Full Text] [Related]
16. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.
Lauro S; Trasatti L; Bordin F; Lanzetta G; Bria E; Gelibter A; Reale MG; Vecchione A
Anticancer Res; 1999; 19(4C):3511-5. PubMed ID: 10629644
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of TPS, CEA and CA 15-3 in breast cancer patients.
Blijlevens NM; Oosterhuis WP; Oosten HR; Mulder NH
Anticancer Res; 1995; 15(6B):2711-6. PubMed ID: 8669851
[TBL] [Abstract][Full Text] [Related]
18. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
[TBL] [Abstract][Full Text] [Related]
19. Serum CYFRA 21-1 (cytokeratin-19 fragments) is a useful tumour marker for detecting disease relapse and assessing treatment efficacy in breast cancer.
Nakata B; Takashima T; Ogawa Y; Ishikawa T; Hirakawa K
Br J Cancer; 2004 Aug; 91(5):873-8. PubMed ID: 15280913
[TBL] [Abstract][Full Text] [Related]
20. [Immunohistochemical evaluation of several tumor markers (CEA, ferritin, Ca) and their correlation with estro-progestin receptor state in neoplasms].
Forti E; Wolf D; Melia M
Pathologica; 1985; 77(1049):241-9. PubMed ID: 3913892
[No Abstract] [Full Text] [Related]
[Next] [New Search]
